Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06491134 | Liposomal Irinotecan With Cisplatin and Concurrent Radiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 1 | 12 | Hebei Medical University Fourth HospitalOTHER | 0 | Jul 8, 2024 | clinicaltrials |
| NCT06469229 | Performance Evaluation of Urine DNA Methylation Testing for the Detection of Urothelial Carcinoma in Patients With Hematuria | not yet recruiting | — | 1,200 | Changhai HospitalOTHER | 1 | Jul 5, 2024 |
| clinicaltrials |
| NCT06487702 | A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 70 | Rui-hua Xu, MD, PhDOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT05628623 | Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment(ERASE) | not yet recruiting | Phase 2 | 184 | Eastern Cooperative Oncology GroupNETWORK | 0 | Jul 3, 2024 | clinicaltrials |
| NCT06485908 | Axitinib and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and Ependymoma(MEPENDAX) | not yet recruiting | Phase 1 / Phase 2 | 40 | Assistance Publique Hopitaux De MarseilleOTHER | 0 | Jul 3, 2024 | clinicaltrials |
| NCT06482931 | Bleeding in Multiple Myeloma(BiMM) | not yet recruiting | — | 160 | University Medical Center GroningenOTHER | 0 | Jul 1, 2024 | clinicaltrials |
| NCT06462105 | Liposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung Cancer | not yet recruiting | N/A | 60 | Zhou ChengzhiOTHER | 0 | Jun 28, 2024 | clinicaltrials |
| NCT06472479 | LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma | not yet recruiting | N/A | 66 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT06480630 | Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Diseases | not yet recruiting | Phase 2 | 39 | Anhui Provincial HospitalOTHER_GOV | 1 | Jun 28, 2024 | clinicaltrials |
| NCT06480721 | FET-PET-Guided Management of Pseudoprogression in Glioblastoma(FET-POPPING) | not yet recruiting | N/A | 144 | Veerle RuijtersOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT06477939 | Study of Adding or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Radiation ThErapy and TEmozolomide in Newly Diagnosed GLioblastoma (GBM) Patients(THREE-GLEES) | not yet recruiting | Phase 3 | 554 | Institut de cancérologie Strasbourg EuropeOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06478264 | A Study of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma | not yet recruiting | Phase 2 | 40 | Zhangzhou Municipal HospitalOTHER | 0 | Jun 27, 2024 | clinicaltrials |
| NCT06475755 | Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC | not yet recruiting | Phase 2 | 178 | Tang-Du HospitalOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06472752 | Neoadjuvant Radiotherapy for High-risk UTUC(LUXUS07) | not yet recruiting | — | 40 | Peking University First HospitalOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06472895 | A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jun 25, 2024 | clinicaltrials |
| NCT06465446 | A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma | not yet recruiting | Phase 3 | 202 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 0 | Jun 24, 2024 | clinicaltrials |
| NCT06470880 | Circulating Tumour DNA Guided Adaptive BRAF and MEK Inhibitor Therapy(DyNAMIc) | not yet recruiting | Phase 2 | 40 | The Christie NHS Foundation TrustOTHER | 0 | Jun 24, 2024 | clinicaltrials |
| NCT06468644 | Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 60 | Fujian Cancer HospitalOTHER_GOV | 0 | Jun 21, 2024 | clinicaltrials |
| NCT06468670 | Short-course Radiotherapy Combined With Sintilimab for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 0 | Jun 21, 2024 | clinicaltrials |
| NCT06463548 | Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma | not yet recruiting | N/A | 30 | Yunpeng LiuOTHER | 1 | Jun 18, 2024 | clinicaltrials |
| NCT06463327 | ACHIEVE2 - Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)/AML(ACHIEVE2) | not yet recruiting | Phase 1 | 69 | TC BiopharmINDUSTRY | 0 | Jun 17, 2024 | clinicaltrials |
| NCT06448611 | Identification and Characterization of Circulating Tumor Cells Before and After Treatment (Surgery and Radiotherapy) in a Cohort of Patients Treated for Resectable Stage I-III Merkel Cell Carcinoma(MERCCALIBI) | not yet recruiting | — | 25 | University Hospital, MontpellierOTHER | 0 | Jun 13, 2024 | clinicaltrials |
| NCT06454435 | Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer | not yet recruiting | Phase 2 | 158 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT06454890 | Clinical Study of Trop2 CAR-NK in the Treatment of Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC) | not yet recruiting | Phase 1 / Phase 2 | 50 | Henan Cancer HospitalOTHER_GOV | 0 | Jun 12, 2024 | clinicaltrials |
| NCT06326853 | Neuroendocrine Mechanisms in Adiposity: An Integrated Approach to the Characterization of Potential Pharmacological Novel Targets Based on Experimental and Clinical Models | not yet recruiting | — | 200 | IRCCS San RaffaeleOTHER | 0 | Jun 11, 2024 | clinicaltrials |
| NCT06452433 | Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer. | not yet recruiting | Phase 2 | 91 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jun 11, 2024 | clinicaltrials |
| NCT06449846 | Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma | not yet recruiting | — | 152 | Zhujiang HospitalOTHER | 1 | Jun 10, 2024 | clinicaltrials |
| NCT06450821 | PROSpECT-PRIOR-2-CHEMO: PRIOR Dental Intervention Before Chemo to Reduce Chemotherapy Complications | not yet recruiting | N/A | 60 | University of LeedsOTHER | 1 | Jun 10, 2024 | clinicaltrials |
| NCT06402175 | Characteristics and Outcomes of Patients With Hematological Malignancies | not yet recruiting | — | 100 | Assiut UniversityOTHER | 0 | Jun 5, 2024 | clinicaltrials |
| NCT06297772 | Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR | not yet recruiting | Phase 3 | 220 | Ruijin HospitalOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06441045 | Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI | not yet recruiting | Phase 2 | 112 | Fujian Cancer HospitalOTHER_GOV | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06441084 | A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation | not yet recruiting | Phase 1 | 15 | Nuwacell Biotechnologies Co., Ltd.INDUSTRY | 0 | Jun 4, 2024 | clinicaltrials |
| NCT06441097 | Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL | not yet recruiting | Phase 2 | 152 | Ruijin HospitalOTHER | 0 | Jun 4, 2024 | clinicaltrials |
| NCT06441344 | Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell(SCLC) | not yet recruiting | Phase 3 | 136 | Taizhou HospitalOTHER | 0 | Jun 4, 2024 | clinicaltrials |
| NCT06442605 | Clinical Research on the Application of Single-channel Uterine Fibroid Morcellation System in Laparoscopic Myomectomy | not yet recruiting | N/A | 22 | First People's Hospital of HangzhouOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06438939 | NBI for Early Diagnosis of OPMD/OSCC(NBI_Oral) | not yet recruiting | N/A | 480 | Cardarelli HospitalOTHER | 1 | Jun 3, 2024 | clinicaltrials |
| NCT06439550 | Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC | not yet recruiting | Phase 2 | 42 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Jun 3, 2024 | clinicaltrials |
| NCT06434740 | A Study of SBRT Combined With Puterizumab in Intrapulmonary Metastasis From NSCLC | not yet recruiting | Phase 2 | 37 | Sir Run Run Shaw HospitalOTHER | 0 | May 30, 2024 | clinicaltrials |
| NCT06436144 | Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC | not yet recruiting | Phase 2 | 93 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 0 | May 30, 2024 | clinicaltrials |
| NCT06426797 | Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 25 | Peking University People's HospitalOTHER | 0 | May 23, 2024 | clinicaltrials |
| NCT06427213 | This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma | not yet recruiting | Phase 2 | 41 | Henan Cancer HospitalOTHER_GOV | 0 | May 23, 2024 | clinicaltrials |
| NCT06418516 | Early Detection of Esophageal Squamous Cancer With the Capsule Sponge Device(ANGELA) | not yet recruiting | N/A | 340 | Centre of Postgraduate Medical EducationOTHER | 0 | May 17, 2024 | clinicaltrials |
| NCT06414915 | Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation | not yet recruiting | Phase 2 | 29 | National Cancer Center, ChinaOTHER | 0 | May 16, 2024 | clinicaltrials |
| NCT06416267 | Risk and Clinical Consequences of Low Count Monoclonal B-cell Lymphocytosis (LC MBL)(MBL RiskConseq) | not yet recruiting | — | 1,500 | University of HaifaOTHER | 0 | May 16, 2024 | clinicaltrials |
| NCT06416930 | Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma | not yet recruiting | Phase 2 | 59 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | May 16, 2024 | clinicaltrials |
| NCT05982275 | Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant(CARTemis-1) | not yet recruiting | Phase 1 / Phase 2 | 25 | Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT06067620 | Robotic Right Hemicolectomy Versus Laparoscopic Right Hemicolectomy(PRORHEM) | not yet recruiting | N/A | 70 | Jeremy MeyerOTHER | 0 | May 10, 2024 | clinicaltrials |
| NCT06364033 | Biological and Clinical Efficacy of Shingrix in Patients With CLL | not yet recruiting | N/A | 312 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06407310 | Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer | not yet recruiting | Phase 2 | 25 | Tel Aviv Medical CenterOTHER | 0 | May 9, 2024 | clinicaltrials |
| NCT05718986 | Familial B-cell Lymphoproliferative Disorders(Familial_LPD) | not yet recruiting | — | 1,000 | University of HaifaOTHER | 0 | May 8, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jul 8, 2024source: clinicaltrials